Artificial intelligence is increasingly harnessed to improve immunotherapy and protein engineering. Researchers developed BATMAN, a Bayesian model trained on a comprehensive T cell receptor-peptide interaction database (BATCAVE), to accurately predict peptide-TCR binding and reduce off-target effects in TCR therapies. Separately, the Baker lab used AI to design highly specific protein binders targeting diverse peptide-MHC complexes, accelerating the development of scalable personalized immunotherapies. These AI-driven platforms enhance targeting precision and speed drug discovery processes in immuno-oncology.